Top Ten Equity Holdings and Exposures
Source: RNS
5th November 2024
Polar Capital Global Healthcare Trust plc (the "Company")
Top Ten Equity Holdings and Sector and Geographic Exposure as at 31st October 2024 full Portfolio listing as at 30th September 2024 available from company's website.
Polar Capital Global Healthcare Trust plc is pleased to announce that as at 31st October 2024 the top ten equity holdings and the sector and geographic breakdown were as follows:
|
Top 10 Holdings |
% |
|
Eli Lilly & Co |
8.3% |
|
UnitedHealth Group |
7.6% |
|
Novo Nordisk A/S |
6.0% |
|
AbbVie |
5.0% |
|
Roche |
4.5% |
|
Sandoz Group AG |
3.5% |
|
Sanofi |
3.3% |
|
Terumo Corp |
3.3% |
|
Fresenius SE & Co KGaA |
3.2% |
|
Intuitive Surgical |
3.2% |
|
Total |
47.9% |
|
Sector Exposure |
% |
|
Pharmaceuticals |
31.6% |
|
Biotechnology |
20.8% |
|
Healthcare Equipment |
15.5% |
|
Life Sciences Tools & Services |
8.2% |
|
Managed Healthcare |
7.6% |
|
Healthcare Supplies |
5.2% |
|
Healthcare Services |
3.2% |
|
Healthcare Facilities |
2.9% |
|
Healthcare Technology |
2.3% |
|
Metal, Glass & Plastic Containers |
1.9% |
|
Healthcare Distributors |
0.8% |
|
Cash |
0.1% |
|
Total |
100.0% |
|
Geographic Exposure |
% |
|
United States |
46.1% |
|
Switzerland |
12.9% |
|
Denmark |
11.4% |
|
Japan |
6.2% |
|
France |
5.7% |
|
Germany |
3.2% |
|
Belgium |
3.1% |
|
Sweden |
3.1% |
|
Netherlands |
3.1% |
|
United Kingdom |
2.4% |
|
Italy |
1.9% |
|
Ireland |
0.8% |
|
Cash |
0.1% |
|
Total |
100.0% |
The monthly factsheet will usually be available on the Company's website on the 10th working day after the month end and includes a commentary by the investment manager. www.Polarcapitalhealthcaretrust.com
Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
